Featured Sessions in 2016:

• Predicting drug effi cacy using integrative models for chronic respiratory diseases

• New approaches for COPD drug development: An opportunity for disease interception

• Advances in device and formulation technologies for pulmonary drug delivery

Featured Speakers:

• Stephen Beckman, Head of Global Respiratory and Allergy, Mylan, Inc.

• Dr Neelima Khairatkar Joshi, Sr Vice President, Glenmark Pharmaceuticals

• Dr Mario Scuri, Head Respiratory Unit, Chiesi Pharmaceuticals

• Dr Frank Thielmann, Lead Inhalation New Solids, Novartis Pharma AG

• Dr Christopher Stevenson, Venture Leader, COPD Interception, Janssen Pharmaceutical Companies of Johnson & Johnson

• Dr Jonathan Phillips, Principal Scientist, Amgen

• Dr Beverley Patterson, Inhalation Clinical Associate Director, Actavis